paracetamolWhat was measured
Measured, with no finding
183 endpoints
Show what was measuredHide what was measured
Failure of ductal closure of a patent ductus arteriosus after paracetamol treatment versus ibuprofen, indomethacin, or placebo/no intervention, in preterm/low-birth-weight infants
increases
Not recorded as a finding: this platform holds no node for the endpoint
Moderate-quality evidence according to GRADE suggests that paracetamol is as effective as ibuprofen; low-quality evidence suggests paracetamol to be more effective than placebo or no intervention; and low-quality evidence suggests paracetamol as effective as indomethacin in closing a PDA.
PMID 31985831 · one of two readings recorded this
failure to close PDA, paracetamol vs indomethacin
no effect
There was no significant difference in the failure to close a PDA (typical RR 0.96, 95% CI 0.55 to 1.65; I² = 11%; typical RD -0.01, 95% CI -0.09 to 0.08; I² = 17%) (low quality of evidence).
PMID 31985831 · one of two readings recorded this
Neurodevelopmental outcome at 18-24 months, vs ibuprofen
no effect, n = 61
There were no significant differences in the neurological outcomes at 18 to 24 months (n = 61); (low quality of evidence).
PMID 31985831 · one of two readings recorded this
serum creatinine, paracetamol vs ibuprofen
decreases
The serum levels of creatinine were lower in the paracetamol group compared with the ibuprofen group in four studies (moderate quality of evidence), as were serum bilirubin levels following treatment in two studies (n = 290).
PMID 31985831 · one of two readings recorded this
all-cause mortality and liver transplantation, N-acetylcysteine vs placebo, in non-paracetamol-induced acute liver failure
no effect, RR 0.88, 95% CI 0.57 to 1.37 (adults, 21-day mortality)
Not recorded as a finding: the paper never mentions the compound
For all-cause mortality at 21 days between adults receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (N-acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence).
PMID 33294991 · one of two readings recorded this
All-cause mortality at 21 days (adults) / one year (children)
no effect
For all-cause mortality at 21 days between adults receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (N-acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence).
PMID 33294991 · one of two readings recorded this
all-cause mortality at 21 days, adults
no effect, RR 0.88, 95% CI 0.57 to 1.37
For all-cause mortality at 21 days between adults receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (N-acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence).
PMID 33294991 · one of two readings recorded this
all-cause mortality at one year, children
no effect, RR 1.47, 95% CI 0.85 to 2.53
Similarly, for all-cause mortality at one year between children receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (25/92 (27.2%) versus 17/92 (18.5%); RR 1.47, 95% CI 0.85 to 2.53; low certainty evidence).
PMID 33294991 · one of two readings recorded this
Liver transplantation
no effect
For liver transplantation at 21 days in the trial with adults, there was inconclusive evidence of effect (RR 0.72, 95% CI 0.49 to 1.06; low certainty evidence).
PMID 33294991 · one of two readings recorded this
Serious adverse events (children)
no effect, RR 1.25, 95% CI 0.35 to 4.51
There was inconclusive evidence of effect on serious adverse events in the trial with children (RR 1.25, 95% CI 0.35 to 4.51; low certainty evidence).
PMID 33294991 · one of two readings recorded this
need for additional pain relief
decreases, RR 0.34, 95% CI 0.21 to 0.55, n = 1132
fewer women may need additional pain relief with paracetamol compared with placebo (average RR 0.34, 95% CI 0.21 to 0.55; 8 trials, 1132 women).
PMID 34559424 · one of two readings recorded this
pain relief (SMD), exercise vs usual care
increases
For pain relief, exercise was more effective than usual care at or nearest to four (SMD=1.31, 95% CrI 0.61 to 2.01), eight (SMD=0.78, 95% CrI 0.58 to 0.98) and 24 weeks (SMD=0.19, 95% CrI 0.00 to 0.38).
PMID 36593092 · one of two readings recorded this
Adverse events, paracetamol+NSAID combination
no effect
Paracetamol plus an NSAID did not increase the risk of AEs in low back pain or osteoarthritis compared to their NSAID monotherapy or placebo (comparison 1.6.1–1.6.5).
PMID 38937394 · one of two readings recorded this
Adverse events, paracetamol+opioid combination
increases
Five out of the nine comparisons of paracetamol plus an opioid analgesic (tramadol or oxycodone) compared with placebo increased the risk of adverse events in low back pain and osteoarthritis (comparison 1.6.7, 1.6.8, 1.6.10, 1.6.11, 1.6.14).
PMID 38937394 · one of two readings recorded this
adverse events, paracetamol plus opioid vs placebo
increases
Five out of the nine comparisons of paracetamol plus an opioid analgesic (tramadol or oxycodone) compared with placebo increased the risk of adverse events in low back pain and osteoarthritis (comparison 1.6.7, 1.6.8, 1.6.10, 1.6.11, 1.6.14).
PMID 38937394 · one of two readings recorded this
disability score, low back pain, paracetamol plus ibuprofen vs ibuprofen, immediate term
decreases, MD -9.2, 95% CI -16.8 to -1.6
Paracetamol plus NSAID combination therapy improved disability scores in low back pain in one combination, paracetamol plus ibuprofen versus ibuprofen, immediate term (MD −9.2, 95% CI −16.8 to −1.6; one study; moderate evidence).
PMID 38937394 · one of two readings recorded this
Disability scores
decreases, MD -9.2, 95% CI -16.8 to -1.6 (paracetamol+ibuprofen vs ibuprofen, LBP, immediate term)
Paracetamol plus NSAID combination therapy improved disability scores in low back pain in one combination, paracetamol plus ibuprofen versus ibuprofen, immediate term (MD −9.2, 95% CI −16.8 to −1.6; one study; moderate evidence).
PMID 38937394 · one of two readings recorded this
Low back pain and osteoarthritis pain intensity on VAS/NRS/categorical pain scales, mean difference, by specific paracetamol combination versus monotherapy or placebo and timepoint
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Paracetamol plus tramadol reduced pain compared with placebo at intermediate term for low back pain (MD −11.7, 95% CI −19.2 to −4.3; two studies, very low evidence) and osteoarthritis (MD −6.8, 95% CI −12.7 to −0.9; one study, moderate evidence).
PMID 38937394 · one of two readings recorded this
Pain intensity, paracetamol+tramadol vs placebo
decreases, MD -11.7, 95% CI -19.2 to -4.3 (LBP, intermediate term); MD -6.8, 95% CI -12.7 to -0.9 (OA, intermediate term)
Paracetamol plus tramadol reduced pain compared with placebo at intermediate term for low back pain (MD −11.7, 95% CI −19.2 to −4.3; two studies, very low evidence) and osteoarthritis (MD −6.8, 95% CI −12.7 to −0.9; one study, moderate evidence).
PMID 38937394 · one of two readings recorded this
pain, low back pain and osteoarthritis, paracetamol plus tramadol vs placebo, intermediate term
decreases, LBP: MD -11.7, 95% CI -19.2 to -4.3; OA: MD -6.8, 95% CI -12.7 to -0.9
Paracetamol plus tramadol reduced pain compared with placebo at intermediate term for low back pain (MD −11.7, 95% CI −19.2 to −4.3; two studies, very low evidence) and osteoarthritis (MD −6.8, 95% CI −12.7 to −0.9; one study, moderate evidence).
PMID 38937394 · one of two readings recorded this
quality of life (SF-36), paracetamol plus tramadol vs placebo
no effect
Paracetamol plus tramadol did not improve quality of life compared with placebo in low back pain or osteoarthritis populations (ESM).
PMID 38937394 · one of two readings recorded this
Quality of life (SF-36)
no effect
Paracetamol plus tramadol did not improve quality of life compared with placebo in low back pain or osteoarthritis populations (ESM).
PMID 38937394 · one of two readings recorded this
serious adverse events, paracetamol combination therapies vs individual controls
no effect
No combination therapy increased the risk of SAEs compared to individual controls (ESM).
PMID 38937394 · one of two readings recorded this
mortality and transplant-free survival by acetaminophen exposure level (high, medium, low, none by history, serum level or APAP-CYS adducts) in viral hepatitis-associated acute liver failure
no effect, high versus no exposure groups not statistically different after adjustment
Not recorded as a finding: another reason, stated per paper
However, the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences.
PMID 38994834 · one of two readings recorded this
mortality and transplant-free survival by acetaminophen exposure level (high, medium, low, none) in viral hepatitis-associated acute liver failure
no effect, high versus no exposure groups not statistically different after adjustment
Not recorded as a finding: the paper never states the instrument the node requires
However, the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences.
PMID 38994834 · one of two readings recorded this
mortality and transplant-free survival, high versus no APAP exposure (adjusted)
no effect, n = 356
the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences
PMID 38994834 · one of two readings recorded this
mortality
increases, n = 356
Mortality was the highest (51.6%, 21.4%, 28.8%, and 30.5%), and transplant-free survival was the lowest (22.6%, 44.6%, 41.5%, and 40.4%) in the high exposure group compared with medium, low, and no exposure groups
PMID 38994834 · one of two readings recorded this
patients with evidence of APAP use among AVH-ALF
n = 356
Two hundred five of 356 patients (57.5%) with AVH-ALF had evidence of APAP use
PMID 38994834 · one of two readings recorded this
patients with high or medium APAP exposure
n = 356
87 out of 356 (24%) demonstrated high or medium exposures
PMID 38994834 · one of two readings recorded this
transplant-free survival
decreases, n = 356
Mortality was the highest (51.6%, 21.4%, 28.8%, and 30.5%), and transplant-free survival was the lowest (22.6%, 44.6%, 41.5%, and 40.4%) in the high exposure group compared with medium, low, and no exposure groups
PMID 38994834 · one of two readings recorded this
paracetamol exposure with higher body weight in SMA (simulation)
increases
Simulations revealed that in SMA patients, higher bodyweight was associated with increased exposure to paracetamol and its metabolites
PMID 40040359 · one of two readings recorded this
hospital length of stay
no effect, p = 0.6, n = 38
Hospital length of stay, median (IQR), days | 19 (13–27) | 19 (13–23) | 18 (13–31) | 0.6
PMID 40974583 · one of two readings recorded this
duration of mechanical ventilation
no effect, p = 0.085, n = 38
Duration of MV, median (IQR), h | 326 (223–383) | 250 (160–370) | 339 (233–470) | 0.085
PMID 40974583 · one of two readings recorded this
albumin rate of change
no effect, p = 0.75
Both cohorts exhibited pronounced hypoalbuminemia from baseline, which worsened over time, with similar rates of change (p = 0.75)
PMID 40974583 · one of two readings recorded this
arterial pH during CRRT
decreases, p = 0.018
the Phoxilium® group experienced a significant decrease in median arterial pH and standard base excess, remaining within normal limits, but lower than the Accusol® group (p = 0.018 and p = 0.046, respectively)
PMID 40974583 · one of two readings recorded this
baseline age
p = 0.012, n = 38
Age, median (IQR), years | 40 (28–48) | 29 (27–38) | 45 (38–52) | 0.012
PMID 40974583 · one of two readings recorded this
baseline arterial pH
p = 0.042, n = 38
Arterial pH, median (IQR) | 7.39 (7.32 to 7.45) | 7.45 (7.39 to 7.46) | 7.35 (7.30 to 7.42) | 0.042
PMID 40974583 · one of two readings recorded this
baseline base excess
p = 0.014, n = 38
Base excess, median (IQR), mmol/L | −5.1 (−9.2 to −0.4) | −0.5 (−4.8 to 1.7) | −7.1 (−9.7 to −2.8) | 0.014
PMID 40974583 · one of two readings recorded this
baseline bicarbonate
p = 0.02, n = 38
Bicarbonate, median (IQR), mmol/L | 19.0 (15.3 to 23.0) | 22.5 (19.0 to 25.0) | 17.0 (14.8 to 21.0) | 0.020
PMID 40974583 · one of two readings recorded this
baseline INR
no effect, p = 0.86, n = 38
INR, median (IQR) | 4.45 (3.10 to 6.08) | 4.40 (2.98 to 5.43) | 4.60 (3.10 to 6.28) | 0.86
PMID 40974583 · one of two readings recorded this
baseline ionised calcium
no effect, p = 0.082, n = 38
Ionised calcium, median (IQR), mmol/L | 1.12 (1.04 to 1.16) | 1.13 (1.10 to 1.19) | 1.09 (1.00 to 1.15) | 0.082
PMID 40974583 · one of two readings recorded this
baseline lactate
no effect, p = 0.14, n = 38
Lactate, median (IQR), mmol/L | 3.9 (2.6 to 8.1) | 3.2 (2.3 to 4.8) | 5.0 (3.0 to 10.5) | 0.14
PMID 40974583 · one of two readings recorded this
baseline peak ammonia
no effect, p = 0.86, n = 38
Peak ammonia, median (IQR), mmol/L | 240 (151 to 335) | 258 (152 to 284) | 212 (107 to 347) | 0.86
PMID 40974583 · one of two readings recorded this
baseline serum phosphate
no effect, p = 0.27, n = 38
Phosphate, median (IQR), mmol/L | 0.97 (0.66 to 1.22) | 0.74 (0.65 to 1.15) | 1.11 (0.80 to 1.25) | 0.27
PMID 40974583 · one of two readings recorded this
burden of hypophosphataemia (proportion of phosphate readings below threshold)
decreases, p = 0.001, n = 38
Burden of hypophosphataemiaa, median (IQR), % | 33 (20–50) | 13 (2–33) | 44 (29–51) | 0.001
PMID 40974583 · one of two readings recorded this
CRRT effluent dose
no effect, p = 0.21, n = 38
Effluent dose, median (IQR), mL/kg/h | 45 (39–63) | 54 (41–72) | 43 (38–56) | 0.21
PMID 40974583 · one of two readings recorded this
cumulative phosphate supplementation dose (mixed model reading)
decreases, p = 0.011
patients in the Accusol® group required more phosphate supplementation, with a median cumulative dose of 100 (35–180) mmol compared to 45 (20–70) mmol in the Phoxilium® group (p = 0.011)
PMID 40974583 · one of two readings recorded this
delivered versus prescribed CRRT dose
increases, p = 0.019, n = 38
Delivered vs. prescribed dose, % (IQR) | 94.3 (92.6–96.5) | 96.0 (94.4–96.6) | 93.3 (91.6–95.7) | 0.019
PMID 40974583 · one of two readings recorded this
hospital mortality
no effect, p = 0.6, n = 38
Hospital mortality, n (%) | 4 (11) | 2 (14) | 2 (8·3) | 0.6
PMID 40974583 · one of two readings recorded this
ICU length of stay
no effect, p = 0.24, n = 38
ICU length of stay, median (IQR), days | 13 (7–19) | 13 (9–16) | 13 (6–20) | 0.24
PMID 40974583 · one of two readings recorded this
ICU mortality adjusted for APACHE III
no effect, p = 0.5, n = 38
After adjusting for APACHE III scores, Phoxilium® was not associated with reduced ICU mortality (odds ratio, 0.47 [95% CI: 0.05–4.48]; p = 0.50)
PMID 40974583 · one of two readings recorded this
ICU mortality
no effect, p = 0.6, n = 38
ICU mortality, n (%) | 4 (11) | 2 (14) | 2 (8·3) | 0.6
PMID 40974583 · one of two readings recorded this
incident hypophosphataemia
decreases, p = 0.001, n = 38
Incident hypophosphataemia, n (%) | 32 (84) | 8 (57) | 24 (100) | 0.001
PMID 40974583 · one of two readings recorded this
incident severe hypophosphataemia (phosphate <0.32 mmol/L) within 168 h
decreases, p = 0.014, n = 38
Incident severe hypophosphataemia, n (%) | 9 (24) | 0 (0) | 9 (38) | 0.014
PMID 40974583 · one of two readings recorded this
ionised calcium over first 72 h
decreases, p = 0.001
Over the first 72 h, median ionised calcium in the Accusol® group rapidly increased and stabilised around 1.3 mmol/L, while the Phoxilium® group maintained lower levels (p < 0.001)
PMID 40974583 · one of two readings recorded this
lactate at baseline
decreases, p = 0.001
Lactate concentrations were higher at baseline in the Accusol® group (p < 0.001)
PMID 40974583 · one of two readings recorded this
peak ALT at baseline
no effect, p = 0.82, n = 38
Peak ALT, median (IQR), IU | 6,495 (4,088 to 10,602) | 6,838 (4,966 to 8,938) | 6,338 (3,744 to 11,655) | 0.82
PMID 40974583 · one of two readings recorded this
peak GGT at baseline
decreases, p = 0.046, n = 38
Peak GGT, median (IQR), IU | 120 (74 to 222) | 90 (41 to 161) | 135 (101 to 240) | 0.046
PMID 40974583 · one of two readings recorded this
phosphate level change rate, fluid type by time interaction
increases, p = 0.001
A significant interaction between fluid type and time (p < 0.001) indicated differing rates of phosphate level changes, with the Phoxilium® group improving more rapidly
PMID 40974583 · one of two readings recorded this
phosphate supplementation
decreases, p = 0.008, n = 38
Phosphate supplementation, median (IQR), mmol | 80 (40–190) | 45 (20–70) | 100 (60–210) | 0.008
PMID 40974583 · one of two readings recorded this
rate of change in ionised calcium, fluid type by time interaction
no effect, p = 0.232
the rate of change in ionised calcium did not differ significantly (interaction p = 0.232)
PMID 40974583 · one of two readings recorded this
serum phosphate after CRRT initiation, Accusol® group
decreases, p = 0.001, n = 24
The Accusol® group experienced a decline in median phosphate levels from 1.11 (0.80–1.25) to 0.62 (0.54–0.78) mmol/L after 12–18 h, remaining significantly lower than the Phoxilium® group throughout the study period (p < 0.001)
PMID 40974583 · one of two readings recorded this
serum phosphate after CRRT initiation, Phoxilium® group
increases, n = 14
In contrast, the Phoxilium® group experienced an increase from 0.74 (0.65–1.15) to 1.09 (0.94–1.20) mmol/L
PMID 40974583 · one of two readings recorded this
standard base excess during CRRT
decreases, p = 0.046
the Phoxilium® group experienced a significant decrease in median arterial pH and standard base excess, remaining within normal limits, but lower than the Accusol® group (p = 0.018 and p = 0.046, respectively)
PMID 40974583 · one of two readings recorded this
total CRRT duration
no effect, p = 0.24, n = 38
Total CRRT durationc, median (IQR), h | 153 (96–157) | 155 (127–162) | 149 (83–156) | 0.24
PMID 40974583 · one of two readings recorded this
transplant-free survival
no effect, p = 0.99, n = 38
Transplant-free survival, n (%) | 32 (84) | 12 (86) | 20 (83) | 0.99
PMID 40974583 · one of two readings recorded this
body mass index
no effect, p = 0.239
Body mass index (kg/m2) | 21 (19–26) | 23 (21–27) | 24 (20–26) | 0.239
PMID 40990326 · one of two readings recorded this
age
no effect, p = 0.334
Age (years) | 23 (21–42) | 34 (22–57) | 26 (20–47) | 0.334
PMID 40990326 · one of two readings recorded this
change in half-life, first to second
decreases, p = 0.001, n = 71
First–second | −1.9 (−3.5–−1.0) | 71 | −4.9 (−8.7 to −2.5) † | 26 | −1.8 (−2.0 to −1.1) † | 20 | −1.1 (−1.9 to −0.4) † | 25 | <0.001
PMID 40990326 · one of two readings recorded this
deceased, n (%)
p = 0.094
Deceased; n (%) | 3 (12) | 0 (0) | 0 (0) | 0.094 †
PMID 40990326 · one of two readings recorded this
first half-life
p = 0.001, n = 71
First | 4.6 (3.5–8.2) | 71 | 9.3 (7.8–11.7) | 26 | 4.5 (4.2–4.8) | 20 | 3.0 (2.4–3.6) | 25 | <0.001
PMID 40990326 · one of two readings recorded this
first paracetamol concentration
no effect, p = 0.52
First paracetamol concentration (mg/L) | 185 (143–326) | 185 (129–242) | 172 (142–209) | 0.520
PMID 40990326 · one of two readings recorded this
fourth half-life
n = 4
Fourth | 2.0 (1.9–8.9) | 4 | 2.0 (1.9–8.9) | 4 | — | 0 | — | 0 | —
PMID 40990326 · one of two readings recorded this
ingested dose per bodyweight
no effect, p = 0.243
Ingested dose per bodyweight (mg/kg) | 463 (300–655) | 340 (218–667) | 326 (267–417) | 0.243
PMID 40990326 · one of two readings recorded this
ingested dose
no effect, p = 0.318
Ingested dose (g) | 28 (18–50) | 22 (15–50) | 23 (18–28) | 0.318
PMID 40990326 · one of two readings recorded this
paracetamol concentration, sample 1
no effect, p = 0.52, n = 71
Sample 1 | 175 (142–248) | 71 | 185 (143–326) | 26 | 185 (129–242) | 20 | 172 (142–209) | 25 | 0.520
PMID 40990326 · one of two readings recorded this
paracetamol concentration, sample 2
p = 0.001, n = 71
Sample 2 | 70 (46–103) | 71 | 97 (70–198) | 26 | 64 (43–101) | 20 | 51 (24–75) | 25 | <0.001
PMID 40990326 · one of two readings recorded this
paracetamol concentration, sample 3
p = 0.001, n = 71
Sample 3 | 7.7 (0.1–23) | 71 | 26 (13–52) | 26 | 7 (5–15) | 20 | 0.1 (0.1–5) | 25 | <0.001
PMID 40990326 · one of two readings recorded this
paracetamol concentration, sample 4
p = 0.224, n = 18
Sample 4 | 6.6 (0.1–18) | 18 | 8.1 (5.3–28) | 13 | 0.1 (0.1–5) | 4 | 6.4 | 1 | 0.224
PMID 40990326 · one of two readings recorded this
paracetamol concentration, sample 5
n = 4
Sample 5 | 0.1 (0.1–7.0) | 4 | 0.1 (0.1–7.0) | 4 | — | 0 | — | 0 | —
PMID 40990326 · one of two readings recorded this
paracetamol elimination half-life after acute overdose during acetylcysteine treatment, calculated as Ln 2 over the elimination constant from consecutive plasma concentrations, first versus second half-life
decreases, first half-life 4.6 (3.5-8.2) h to second half-life 2.9 (2.1-3.8) h, within-patient, n = 71
Not recorded as a finding: this platform holds no node for the endpoint
The half-life changed from 4.6 (3.5–8.2) h for the first half-life to 2.9 (2.1–3.8) h for the second half-life (P < 0.001).
PMID 40990326 · one of two readings recorded this
paracetamol half-life, first versus second half-life
decreases, p = 0.001, n = 71
The half-life changed from 4.6 (3.5–8.2) h for the first half-life to 2.9 (2.1–3.8) h for the second half-life (P < 0.001)
PMID 40990326 · one of two readings recorded this
paracetamol plasma half-life, first versus second consecutive half-life after acute overdose in acetylcysteine-treated patients
decreases, median half-life 4.6 (3.5-8.2) h first versus 2.9 (2.1-3.8) h second
Not recorded as a finding: the compound is what was measured, not what was given
The half-life changed from 4.6 (3.5–8.2) h for the first half-life to 2.9 (2.1–3.8) h for the second half-life (P < 0.001).
PMID 40990326 · one of two readings recorded this
peak ALT >1000 IU/L, n (%)
p = 0.071
Peak ALT >1000 IU/L; n (%) | 3 (12) | 0 (0) | 0 (0) | 0.071 †
PMID 40990326 · one of two readings recorded this
second half-life
p = 0.001, n = 71
Second | 2.9 (2.1–3.8) | 71 | 4.5 (3.2–5.4) | 26 | 3.0 (2.5–3.6) | 20 | 2.0 (1.2–2.4) | 25 | <0.001
PMID 40990326 · one of two readings recorded this
third half-life
p = 0.104, n = 18
Third | 3.9 (2.3–6.2) | 18 | 6.0 (3.7–6.7) | 13 | 1.7 (0.9–3.1) | 4 | 2.3 | 1 | 0.104
PMID 40990326 · one of two readings recorded this
time between samples 1-2
no effect, p = 0.195, n = 71
Between samples 1-2 | 5.6 (4.0–9.5) | 71 | 6.8 (4.1–11.0) | 26 | 5.1 (4.0–9.1) | 20 | 4.4 (4.0–7.4) | 25 | 0.195
PMID 40990326 · one of two readings recorded this
time between samples 2-3
no effect, p = 0.369, n = 71
Between samples 2-3 | 9.0 (6.4–12.9) | 71 | 8.9 (6.4–11.0) | 26 | 8.5 (6.4–10.4) | 20 | 11.8 (7.0–14.2) | 25 | 0.369
PMID 40990326 · one of two readings recorded this
time between samples 3-4
no effect, p = 0.203, n = 18
Between samples 3-4 | 13.3 (6.4–19.3) | 18 | 16.5 (8.3–24.0) | 13 | 7.4 (6.8–12.8) | 4 | 4.2 | 1 | 0.203
PMID 40990326 · one of two readings recorded this
time between samples 4-5
n = 4
Between samples 4-5 | 15.9 (15.3–19.6) | 4 | 15.9 (15.3–19.6) | 4 | — | 0 | — | 0 | —
PMID 40990326 · one of two readings recorded this
time to acetylcysteine after ingestion
no effect, p = 0.666
Time to acetylcysteine after ingestion (h) | 4.0 (2.3–7.5) | 5.4 (3.0–6.5) | 4.2 (2.5–6.0) | 0.666
PMID 40990326 · one of two readings recorded this
time to first concentration after ingestion
no effect, p = 0.919
Time to first concentration after ingestion (h) | 4.0 (4.0–5.1) | 4.0 (3.8–5.3) | 4.0 (3.9–4.5) | 0.919
PMID 40990326 · one of two readings recorded this
change in NRS
decreases, n = 1241
Change in NRS [Mean ± SD] | 3.9 ± 2.0 | 2.9 ± 2.0 | 4.6 ± 2.1 | 4.0 ± 1.5
PMID 41039602 · one of two readings recorded this
drug-related complications, odds by age
increases, p = 0.0109, n = 1241
Age | 1.02 | 1.00‒ 1.03 | 0.0109
PMID 41039602 · one of two readings recorded this
drug-related complications, odds by sex
no effect, p = 0.0863, n = 1241
Sex (female vs. male) | 1.67 | 0.93‒3.00 | 0.0863
PMID 41039602 · one of two readings recorded this
drug-related complications, odds, nalbuphine + paracetamol versus piritramide
no effect, p = 0.3, n = 1241
the comparison of nalbuphine plus paracetamol vs. piritramide showed no evidence for a difference (OR: 0.75, 95% CI: 0.45–1.24, p = 0.3)
PMID 41039602 · one of two readings recorded this
drug-related complications, odds, paracetamol versus nalbuphine + paracetamol
decreases, p = 0.01, n = 1241
While the comparison of paracetamol vs. nalbuphine plus paracetamol showed lower odds of complications during treatment (OR: 0.17, 95% CI: 0.06–0.49, p < 0.01)
PMID 41039602 · one of two readings recorded this
effective analgesia (NRS ≤ 4 at hospital admission), odds
increases, p = 0.01, n = 1241
While treatment with nalbuphine plus paracetamol increased the odds of achieving NRS ≤ 4 at hospital admission (OR: 3.25, 95% CI: 2.46–4.30, p < 0.01)
PMID 41039602 · one of two readings recorded this
effective analgesia (NRS ≤ 4 at hospital admission), odds
decreases, p = 0.0001, n = 1241
Paracetamol vs. nalbuphine + paracetamol | 0.32 | 0.23‒ 0.45 | < 0.0001
PMID 41039602 · one of two readings recorded this
effective analgesia (NRS ≤ 4 at hospital admission), odds
decreases, p = 0.0001, n = 1241
Piritramide vs. nalbuphine + paracetamol | 0.31 | 0.23‒ 0.41 | < 0.0001
PMID 41039602 · one of two readings recorded this
effective analgesia (NRS ≤ 4), odds by age
no effect, p = 0.7565, n = 1241
Age | 1.00 | 1.00‒1.01 | 0.7565
PMID 41039602 · one of two readings recorded this
effective analgesia (NRS ≤ 4), odds by sex
no effect, p = 0.8395, n = 1241
Sex (female vs. male) | 1.03 | 0.79‒1.33 | 0.8395
PMID 41039602 · one of two readings recorded this
effective analgesia (NRS ≤ 4), odds per initial NRS point
decreases, p = 0.0001, n = 1241
Initial numeric rating scale | 0.66 | 0.60‒ 0.73 | < 0.0001
PMID 41039602 · one of two readings recorded this
effective analgesia, numeric rating scale score of 4 or less at hospital admission, intravenous paracetamol versus nalbuphine plus paracetamol versus piritramide, logistic regression
decreases, paracetamol versus nalbuphine plus paracetamol, OR 0.32, 95% CI 0.23-0.45
Not recorded as a finding: the comparison was against another active treatment
While treatment with nalbuphine plus paracetamol increased the odds of achieving NRS ≤ 4 at hospital admission (OR: 3.25, 95% CI: 2.46–4.30, p < 0.01), treatment with piritramide (OR: 0.31, 95% CI: 0.23–0.41, p < 0.01) or paracetamol (OR: 0.32, 95% CI: 0.23–0.45, p < 0.01) reduced this chance.
PMID 41039602 · one of two readings recorded this
initial NRS
n = 1241
NRS initial [Mean ± SD] | 7.9 ± 1.4 | 6.8 ± 1.4 | 8.2 ± 1.3 | 8.3 ± 1.1
PMID 41039602 · one of two readings recorded this
NRS at hospital admission
n = 1241
NRS hospital admission [Mean ± SD] | 4.0 ± 1.8 | 4.0 ± 1.9 | 3.6 ± 1.9 | 4.3 ± 1.5
PMID 41039602 · one of two readings recorded this
patients achieving NRS ≤ 4 at hospital admission
n = 1241
nalbuphine + paracetamol: n = 236 [47.5%]; piritramide: n = 142 [28.6%]; paracetamol: n = 119 [23.9%]
PMID 41039602 · one of two readings recorded this
patients with NRS reduction ∆NRS < 2
n = 439
Nalbuphine + paracetamol | 29 (6.6%) | 24 (5.5%) | 61 (13.9%) | 91 (20.7%) | 234 (53.5%)
PMID 41039602 · one of two readings recorded this
patients with NRS reduction ∆NRS < 2
n = 291
Paracetamol | 66 (22.7%) | 71 (24.4%) | 61 (21.0%) | 40 (13.7%) | 53 (18.2%)
PMID 41039602 · one of two readings recorded this
patients with NRS reduction ∆NRS < 2
n = 511
Pritramide | 22 (4.3%) | 62 (12.1%) | 102 (20.0%) | 148 (29.0%) | 177 (34.6%)
PMID 41039602 · one of two readings recorded this
patients with NRS reduction ∆NRS > 4
n = 439
Nalbuphine + paracetamol | 29 (6.6%) | 24 (5.5%) | 61 (13.9%) | 91 (20.7%) | 234 (53.5%)
PMID 41039602 · one of two readings recorded this
patients with NRS reduction ∆NRS > 4
n = 291
Paracetamol | 66 (22.7%) | 71 (24.4%) | 61 (21.0%) | 40 (13.7%) | 53 (18.2%)
PMID 41039602 · one of two readings recorded this
patients with NRS reduction ∆NRS > 4
n = 511
Pritramide | 22 (4.3%) | 62 (12.1%) | 102 (20.0%) | 148 (29.0%) | 177 (34.6%)
PMID 41039602 · one of two readings recorded this
total dose of nalbuphine
n = 439
Total dose of nalbuphine (mg) [Mean ± SD] | 14.2 ± 5.9 | - | 14.2 ± 5.9 | -
PMID 41039602 · one of two readings recorded this
total dose of paracetamol
n = 730
Total dose of paracetamol (mg) [Mean ± SD] | 996.1 ± 45.5 | 994.3 ± 49.6 | 997.3 ± 42.7 | -
PMID 41039602 · one of two readings recorded this
total dose of piritramide
n = 511
Total dose of piritramide (mg) [Mean ± SD] | 7.1 ± 3.5 | - | - | 7.1 ± 3.5
PMID 41039602 · one of two readings recorded this
Correlation of miR-122 with ALT
increases, p = 0.03
miR-122 moderately correlated with ALT (r = 0.56, p = 0.03)
PMID 41248904 · one of two readings recorded this
miR-122 ROC area under the curve for paracetamol DILI
n = 38
ROC analysis yielded an area under the curve (AUC) of 0.96
PMID 41248904 · one of two readings recorded this
miR-122 sensitivity at 29.7 pg/mL cut-off
n = 38
92.6% sensitivity (95% CI: 76.6%-98.7%)
PMID 41248904 · one of two readings recorded this
miR-122 specificity at 29.7 pg/mL cut-off
n = 38
89.4% specificity (95% CI: 68.6%-98.1%)
PMID 41248904 · one of two readings recorded this
Serum miR-122 concentration
increases, n = 38
The median miR-122 concentration was significantly elevated at 233.4 pg/mL (IQR: 74.5-363.4) compared to 15.2 pg/mL (IQR: 9.4-24) in the control group
PMID 41248904 · one of two readings recorded this
Serum miR-122 group difference (Mann-Whitney U test)
increases, p = 0.0001, n = 38
The Mann-Whitney U test showed significant group differences (p < 0.0001)
PMID 41248904 · one of two readings recorded this
All childhood cancers
no effect, n = 2754
The main analysis did not yield sufficient evidence to conclude that acetaminophen exposure during pregnancy increases the risk of all childhood cancers
PMID 41342591 · one of two readings recorded this
Childhood bone tumors
unclear
bone tumors (adjusted HR = 1.85; 95% CI, 0.92-3.72)
PMID 41342591 · one of two readings recorded this
Childhood hepatoblastoma
unclear
hepatoblastoma (adjusted HR = 1.73; 95% CI, 0.97-3.10)
PMID 41342591 · one of two readings recorded this
Childhood medulloblastoma
increases
medulloblastoma [adjusted hazard ratio (HR) = 2.43; 95% confidence interval (CI), 1.10-5.39]
PMID 41342591 · one of two readings recorded this
alanine aminotransferase
no effect, p = 0.938, n = 194
Alanine aminotransferase (IU/L)b | 14 (10–21) | 14 (10–20) | 14 (9–28) | 17 (10–27) | 0.938
PMID 41456031 · one of two readings recorded this
serum albumin
decreases, p = 0.011, n = 194
Albumin (g/dL) | 4.5 (4.2–4.8) | 4.6 (4.3–4.8) | 4.3(3.8–4.6) | 4.1 (3.7–4.5) | 0.011c
PMID 41456031 · one of two readings recorded this
age
no effect, p = 0.137, n = 194
Age (year) | 21 (17–32) | 21 (17-32.5) | 23 (18–31) | 16 (15–31) | 0.137
PMID 41456031 · one of two readings recorded this
AUC of elapsed time for predicting toxic APAP concentration after 15 h
p = 0.001
The AUC for predicting toxic APAP concentration 15 h after ingestion using elapsed time was 0.969 (95% CI 0.934–0.989, p < 0.001)
PMID 41456031 · one of two readings recorded this
body weight
no effect, p = 0.689, n = 194
Weight (kg) | 56.0 (50.0–65.0) | 56.0 (50.0-64.5) | 57.0 (48.0–65.0) | 54 (43–66) | 0.689
PMID 41456031 · one of two readings recorded this
elevated liver enzyme, n (%)
no effect, p = 0.132, n = 194
Elevated liver enzyme | 15 (7.7) | 9 (5.7) | 6 (20.0) | 0 (0.0) | 0.132
PMID 41456031 · one of two readings recorded this
ingested dose per kilogram of weight
no effect, p = 0.07, n = 194
Ingested dose per kilogram of weight (mg/kg) | 152.8 (100.0-234.0) | 150.0 (91.6-222.2) | 177.7 (132.3–350.0) | 166.6 (138.8-190.4) | 0.070
PMID 41456031 · one of two readings recorded this
male gender, n (%)
no effect, p = 0.591, n = 194
Gender, Male | 31 (16.0) | 25 (15.9) | 5 (16.7) | 1 (14.3) | 0.591
PMID 41456031 · one of two readings recorded this
N-acetylcysteine treatment, n (%)
no effect, p = 0.163, n = 194
N-acetylcysteine treatment | 158 (81.4) | 125 (79.6) | 27 (90.0) | 6 (85.7) | 0.163
PMID 41456031 · one of two readings recorded this
patients above the 100-treatment line at first APAP test
showed concentrations above the 100-treatment line in the first APAP concentration test, with a median time from ingestion to the first test of 449 min
PMID 41456031 · one of two readings recorded this
patients ingesting at least 10 g or 200 mg/kg APAP
87 patients (44.8%) ingested at least 10 g or 200 mg/kg of APAP, and all received NAC treatment
PMID 41456031 · one of two readings recorded this
patients with detectable or toxic serum APAP concentration after 15 h
A total of 37 patients (19.0%) showed detectable and toxic serum APAP concentrations after 15 h of ingestion
PMID 41456031 · one of two readings recorded this
sensitivity of 612 min cut-off for toxic APAP concentration after 15 h
The sensitivity and specificity of 612 min cut-off value were 100.0% (95% CI 59.0-100.0) and 92.5% (95% CI 87.8–95.8)
PMID 41456031 · one of two readings recorded this
specificity of 612 min cut-off for toxic APAP concentration after 15 h
The sensitivity and specificity of 612 min cut-off value were 100.0% (95% CI 59.0-100.0) and 92.5% (95% CI 87.8–95.8)
PMID 41456031 · one of two readings recorded this
time from ingestion to presentation as predictor of detectable APAP concentration after 15 h (vs undetected)
no effect, p = 0.233
Time from ingestion to presentation [log(minute)] | 1.322 (0.835–2.093) | 0.233 | 1908 (12-283373) | 0.003
PMID 41456031 · one of two readings recorded this
time from ingestion to presentation as predictor of toxic APAP concentration after 15 h (vs undetected)
increases, p = 0.003
elapsed time from ingestion to EMC presentation was found to be a significant independent variable in predicting the toxic concentration 15 h after ingestion compared with the undetected serum levels (OR = 1908.536, 95% CI 12.854–283373.365, p = 0.003)
PMID 41456031 · one of two readings recorded this
time from ingestion to presentation
increases, p = 0.001, n = 194
Time from ingestion to presentation (minute) | 218 (89–431) | 200 (82–380) | 239 (113–467) | 847 (669–871) | < 0.001c
PMID 41456031 · one of two readings recorded this
total ingested dose
no effect, p = 0.074, n = 194
Total ingested dose (g) | 9.0 (5.6–13.0) | 8.8 (5.1–12.7) | 10.2 (8.0–22.0) | 8.0 (6.5–9.7) | 0.074
PMID 41456031 · one of two readings recorded this
Cortical surface area and volume in some regions
decreases, n = 193
Vertex-wise linear mixed effect models showed that exposed children (n = 193; 393 scans) had slightly smaller cortical surface area and volume in some regions compared to non-exposed children
PMID 41496292 · one of two readings recorded this
Cortical surface area and volume in some regions
decreases, n = 21
These results were seemingly driven by long-term exposed children (≥14 days in utero; n = 35; 72 scans, and exposed in all three trimesters, n = 21; 44 scans)
PMID 41496292 · one of two readings recorded this
Cortical surface area and volume in some regions
decreases, n = 35
These results were seemingly driven by long-term exposed children (≥14 days in utero; n = 35; 72 scans, and exposed in all three trimesters, n = 21; 44 scans)
PMID 41496292 · one of two readings recorded this
cortical surface area and volume on MRI, vertex-wise linear mixed effect models
decreases, slightly smaller cortical surface area and volume in some regions
Not recorded as a finding: no outcome node for cortical surface area or volume by MRI
Vertex-wise linear mixed effect models showed that exposed children (n = 193; 393 scans) had slightly smaller cortical surface area and volume in some regions compared to non-exposed children.
PMID 41496292 · one of two readings recorded this
Days of prenatal exposure
n = 193
Days of exposure range from 1 to 128 (mean 8.2)
PMID 41496292 · one of two readings recorded this
Prenatal paracetamol exposure prevalence
n = 447
Among 447 children (229 girls; mean age 8.38 years), 193 (43.2 %) were prenatally exposed.
PMID 41496292 · one of two readings recorded this
working memory capacity and IQ scores in children after prenatal paracetamol exposure; cortical surface area and volume on MRI
no effect
Not recorded as a finding: the paper never states the instrument the node requires
For cognitive abilities, results were reassuring showing no significant effect of prenatal paracetamol exposure on working memory capacity or IQ scores.
PMID 41496292 · one of two readings recorded this
Working memory capacity and IQ scores
no effect
For cognitive abilities, results were reassuring showing no significant effect of prenatal paracetamol exposure on working memory capacity or IQ scores
PMID 41496292 · one of two readings recorded this
Accidental exposures (count of unintentional paracetamol exposures)
n = 17318
There were 17,318 unintentional paracetamol exposures including 10,189 dosing errors and 7129 accidental exposures.
PMID 41803773 · one of two readings recorded this
Dosing errors (count of unintentional paracetamol exposures)
n = 17318
There were 17,318 unintentional paracetamol exposures including 10,189 dosing errors and 7129 accidental exposures.
PMID 41803773 · one of two readings recorded this
Hepatotoxicity among hospitalised exposures
n = 142
No cases of liver transplantation or death were identified and only 3.0% (n = 2) developed hepatotoxicity.
PMID 41803773 · one of two readings recorded this
Hospitalisation among 2021 in-depth exposures
n = 1498
In-depth analysis of exposures from 2021 was done on 1498 exposures (median age 1 year, 54.0% male) with 1.7% (n = 26) requiring hospitalisation.
PMID 41803773 · one of two readings recorded this
N-acetylcysteine treatment among hospitalised exposures
n = 142
Of these, 10.6% (n = 15) were treated with the antidote, N-acetylcysteine.
PMID 41803773 · one of two readings recorded this
Accidental ingestion proportion
n = 197
Accidental ingestion accounted for 49.2% of cases, whereas 50.8% were intentional.
PMID 41998668 · one of two readings recorded this
Asymptomatic at presentation
n = 197
At presentation, 68.5% of patients were asymptomatic, and nausea and vomiting were the most common symptoms (16.2%).
PMID 41998668 · one of two readings recorded this
Gastrointestinal decontamination performed
n = 197
Gastrointestinal decontamination was performed in 81.6% of patients, and 14.7% received N-acetylcysteine therapy.
PMID 41998668 · one of two readings recorded this
Intent of ingestion by sex (accidental more common in boys, intentional in girls)
p = 0.001, n = 197
Accidental ingestion was more common in boys, while intentional ingestion predominated in girls (p < 0.001)
PMID 41998668 · one of two readings recorded this
Intentional ingestion proportion
n = 197
Accidental ingestion accounted for 49.2% of cases, whereas 50.8% were intentional.
PMID 41998668 · one of two readings recorded this
N-acetylcysteine therapy received
n = 197
Gastrointestinal decontamination was performed in 81.6% of patients, and 14.7% received N-acetylcysteine therapy.
PMID 41998668 · one of two readings recorded this
Nausea and vomiting at presentation
n = 197
At presentation, 68.5% of patients were asymptomatic, and nausea and vomiting were the most common symptoms (16.2%).
PMID 41998668 · one of two readings recorded this
Paracetamol ingested alone
n = 197
Paracetamol was ingested alone in 42.1% of patients and in combination with other drugs in 57.9%.
PMID 41998668 · one of two readings recorded this
Paracetamol ingested in combination with other drugs
n = 197
Paracetamol was ingested alone in 42.1% of patients and in combination with other drugs in 57.9%.
PMID 41998668 · one of two readings recorded this
Serum paracetamol above Rumack-Matthew treatment line
n = 197
Only 2 patients (1.0%) had serum paracetamol levels above the treatment line on the Rumack–Matthew nomogram.
PMID 41998668 · one of two readings recorded this
Serum paracetamol above treatment threshold among those measured
n = 137
Serum paracetamol levels were measured in 137 patients (69.5%); of these, 2 (1.5%) had levels above the Rumack–Matthew treatment threshold.
PMID 41998668 · one of two readings recorded this
Time to hospital admission
n = 197
The mean time to hospital admission was 3.1 ± 3.9 hours.
PMID 41998668 · one of two readings recorded this
ADHD diagnosis or ADHD-specific medication prescription in offspring, sibling-matched Cox model
no effect, aHR 1.01; 95% CI 0.93-1.08
Not recorded as a finding: no outcome node for ADHD diagnosis in offspring
In the sibling-matched analyses, prenatal paracetamol exposure was not associated with the risk of ASD (adjusted hazard ratio [aHR], 1.00; 95% CI, 0.91-1.11) or ADHD (aHR, 1.01; 95% CI, 0.93-1.08).
PMID 42371637 · both readings recorded this
ADHD risk
no effect, n = 97285
or ADHD (aHR, 1.01; 95% CI, 0.93-1.08)
PMID 42371637 · one of two readings recorded this
ADHD risk
increases
and ADHD (HR, 1.24; 95% CI, 1.20-1.28)
PMID 42371637 · one of two readings recorded this
Autism spectrum disorder risk
no effect, n = 124333
prenatal paracetamol exposure was not associated with the risk of ASD (adjusted hazard ratio [aHR], 1.00; 95% CI, 0.91-1.11)
PMID 42371637 · one of two readings recorded this
Autism spectrum disorder risk
increases
negative control analyses of prepregnancy exposure for ASD (HR, 1.12; 95% CI, 1.08-1.17)
PMID 42371637 · one of two readings recorded this
Prenatal paracetamol exposure prevalence in initial cohort
n = 708020
From an initial cohort of 708 020 mother-child pairs (approximately 43.3% with prenatally paracetamol exposure)
PMID 42371637 · one of two readings recorded this
ADHD diagnosis (cord plasma acetaminophen biomarker dose-response)
increases, odds of ADHD diagnosis increased 2.25 to 2.86 times
A strong dose-response relationship between fetal acetaminophen exposure, measured by cord plasma biomarkers, and ADHD diagnoses was observed, increasing the odds of an ADHD diagnosis in 2.25 to 2.86 times.
PMID 42500177 · one of two readings recorded this
ADHD diagnosis
increases, odds increased 2.25 to 2.86 times (cord plasma biomarker dose-response)
A strong dose-response relationship between fetal acetaminophen exposure, measured by cord plasma biomarkers, and ADHD diagnoses was observed, increasing the odds of an ADHD diagnosis in 2.25 to 2.86 times.
PMID 42500177 · one of two readings recorded this
ADHD symptoms
increases, RR 1.45, 95% CI 1.18 to 1.78
Self-reported maternal acetaminophen use and an increased risk of ADHD symptoms in children (RR 1.45, 95% CI 1.18 to 1.78) was also noted.
PMID 42500177 · one of two readings recorded this
ASD symptoms presence
no effect, OR 1.16, 95% CI 0.94 to 1.43, p= 0.1719, I2 = 0%
A higher risk of presenting ASD symptoms by 16% was observed, albeit not statistically significant (OR 1.16, 95% CI 0.94 to 1.43, p= 0.1719, I2 = 0%) and with no substantial heterogeneity in the sensitivity analysis (Supplemental material: Figure S2).
PMID 42500177 · one of two readings recorded this
Autism spectrum disorder (ASD) diagnosis and ASD symptoms in offspring, pooled odds ratio across observational cohort studies of prenatal acetaminophen exposure
increases, OR 1.18, 95% CI 1.15 to 1.32, p <0.0001, I2 = 45.9%
Not recorded as a finding: this platform holds no node for the endpoint
The pooled results showed that acetaminophen use during pregnancy increased the risk of ASD diagnosis by 18% (OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%).
PMID 42500177 · one of two readings recorded this
Autism Spectrum Disorder (ASD) diagnosis in offspring, pooled odds ratio across cohort studies
increases, OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%
Not recorded as a finding: this platform holds no node for the endpoint
The pooled results showed that acetaminophen use during pregnancy increased the risk of ASD diagnosis by 18% (OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%).
PMID 42500177 · one of two readings recorded this
Autism spectrum disorder (ASD) diagnosis
increases, OR 1.18, 95% CI 1.15 to 1.32, p <0.0001, I2 = 45.9%
The pooled results showed that acetaminophen use during pregnancy increased the risk of ASD diagnosis by 18% (OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%).
PMID 42500177 · both readings recorded this
Autism spectrum symptoms (CAST or similar screening scores)
increases, OR 1.16, 95% CI 0.94 to 1.43, p = 0.1719, I2 = 0% (not statistically significant)
A higher risk of presenting ASD symptoms by 16% was observed, albeit not statistically significant (OR 1.16, 95% CI 0.94 to 1.43, p= 0.1719, I2 = 0%) and with no substantial heterogeneity in the sensitivity analysis (Supplemental material: Figure S2).
PMID 42500177 · one of two readings recorded this